Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...
Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...
In a groundbreaking discovery, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human ...
In an important discovery, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human immunodeficiency ...
In a randomized trial, ART intensification by doubling the dolutegravir dosage in people with HIV stably suppressed on ...
In 2022, there were up to 1.2 million people with HIV (PWH) and 37,981 new cases of HIV in the United States alone. 1 While impressive advances have been made in HIV treatment and prevention, there ...
Human immunodeficiency virus (HIV) infections are lifelong, potentially life-threatening infections that weaken an individual’s immune system, rendering them susceptible to severe secondary infections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results